Left Menu Image

Nichols Lab



R. Jeremy Nichols
Director of Signal Transduction and LRRK2 Biology

Jeremy Nichols, PhD obtained a BS degree with honors from Austin Peay State University where he was involved in field biology studies of reptile and amphibian populations. He then obtained a PhD in the laboratory of Paula Traktman, PhD at the Medical College of Wisconsin. While there, he studied a novel family of protein kinases called the vaccinia related kinases (VRKs) and found that they regulate a protein required for meiotic cell division. He also studied proteins involved in the infectious cycle of the small pox vaccine agent vaccinia virus, characterizing viral proteins involved in virion entry and virulence. He pursued his interest in cellular signaling with a post-doctoral fellowship at the United Kingdom Medical Research Council Protein Phosphorylation Unit in Dundee, Scotland with Professor Dario Alessi (FRSE, FRS). While there, he sought to unravel the role of LRRK2 in cells and how disease associated mutations cause Parkinson’s disease. He also successfully developed assays for LRRK2 both in vitro and in the cell. He joined The Parkinson’s Institute in 2010 where his LRRK2 investigations can gain greater impact by integration with the clinical resources and basic science research at The Parkinson’s Institute.





Marc Bolliger, Ph.D.
Staff Scientist

PhD in Natural Sciences from Swiss Federal Institute of Technology Zurich (ETH)Diploma in Natural Sciences from Swiss Federal Institute of Technology Zurich (ETH)

I joined the Parkinson's Institute as a Staff Scientist in summer 2013. My projects focus on identifying the kinases and phosphatases that regulate LRRK2.

I earned my Ph.D. in biochemistry from ETH Zürich in 2001. Under the supervision of Dr. Sergio Gloor I discovered two neuroligin genes encoding cell adhesion proteins localized at the synapse. One of them, neuroligin 4, became the first gene shown to be implicated in autism. While working as a Postdoctoral Fellow in Dr. Peter Sonderegger's lab at University of Zürich, I investigated neurotrypsin, a neuronal protease associated with mental retardation. Based on the analysis of transgenic and knockout mice we succeeded in identifying the substrate of neurotrypsin, namely agrin, and a developmental analysis of these mice demonstrated that this proteolytic event regulates the maturation of the neuromuscular junction. Then I joined Dr. Thomas Südhof's lab at Stanford University to follow up on my graduate work. We identified a novel point mutation in neuroligin 4 in autistic patients and demonstrated that this mutation impairs protein folding. In addition, I screened for ligands of a brain-specific G-protein coupled receptor, and studied its signaling upon binding of these ligands.





Tyler Molitor, Ph.D.
Postdoctoral Fellow / Vivarium Manager

Ph.D. in Microbiology and Molecular Genetics, Medical College of Wisconsin B.A. in Biology, Lawrence University


Dr. Molitor focuses on understanding cellular signaling mechanisms, particularly kinase signaling, that go awry in PD. He employs multitude of disciplines and model systems in order to dissect pathologic signaling events. He started his scientific training during his undergraduate years at Lawrence University working to understand senescence (cellular aging) mechanisms in the marchantia polymorpha under Dr. Nicholas Maravolo PhD. His focus on kinase biology began during his doctoral training at the Medical College of Wisconsin under the renowned virologist Dr. Paula Traktman. He examined the influence of the viral F10 kinase on the life-cycle of the vaccinia virus. This research led to a body of work dissecting the mammalian Vaccinia Related Kinase (VRK) family culminating in two single author papers on the role of VRK1 in nuclear envelope breakdown and tumorigenesis in an orthotopic xenograft model of breast cancer. Since joining the PICC he has been working to understand the contribution of the Leucine Rich Repeat Kinase 2 (LRRK2) in Parkinson’s disease (PD) pathogenesis focusing on targeting the kinase domain as a potential therapeutic. In addition Dr. Molitor is also the Vivarium Manager at the Parkinson’s Institute and Clinical Center (PICC). He directs all facets of our research animal colony from regulatory oversight and personnel management to pre-clinical trial design. He has 10 years of experience working with and developing genetic rodent models of disease. Since his assignment we have expanded our colony to include 7 genetic models of PD in the 3 major genetic contributors to PD: leucine-rich-repeat kinase 2 (LRRK2),alpha-synuclein (SNCA) and glucocerebrosidase (GBA). These multiple models will further our investigation of prospective therapeutic for multiple genetic facets of PD.



Schuele Lab



Birgitt Schuele , MD
Associate Professor, Program Director of Gene Discovery and Stem Cell Modeling

Dr. Schuele is an Associate Professor and Director of Gene Discovery and Stem Cell Modeling at the Parkinson’s Institute. 

Dr. Schuele heads the neurogenetics program, which includes clinical genetic studies of families and sporadic cases with parkinsonism. These patient-derived DNA and tissue samples are the core and basis for gene discovery, functional phenotype analysis, and biomarker studies.

Since 2008, she has built a stem cell program developing novel “disease in-a-dish” models of Parkinson’s disease using patient-derived induced pluripotent stem cells. Stem cell-derived neurons are representing a new human cellular model for studying disease mechanisms, the effects of environmental toxicants, and for developing new strategies of innovative drug discovery. 

Current Interests: Neurodegenerative and movement disorders (Parkinson’s disease, parkinsonism, dystonia), neurogenetics, genetics, transcriptional regulation, epigenetics, imprinting, nuclear reprogramming, induced pluripotent stem cells, stem cell pathology, aging, mitochondrial bioenergetics

Personal Research Goals: I would like to make a difference in the lives of patients with Parkinson’s disease. I won’t give up working towards the causes of and better treatments for Parkinson’s disease

Education 2001 MD, Medical University Luebeck, Germany
  2001 Dr. med. Medical University Goettingen, Germany
  Curriculum Vitae

Fun Facts: Always look on the bright side of life, although sometimes it is in the shadows! I am training to run 26.2 miles this year.





Danuta Sastre, Ph.D.

Danuta is a Postdoctoral Associate. She has earned her PhD in Genetics & Molecular Biology in 2015. Her doctoral work focused on regulation of nuclear reprogramming and cancer proliferation by RNA interference. At the Parkinson’s Institute, she is using genome engineering to develop novel gene therapies for Parkinson’s using patient-derived induced pluripotent stem cells.


Current Interests: Disease modeling using induced pluripotent stem cells (iPSC), regenerative medicine, genome engineering (CRISPR/Cas9), gene therapy, RNA interference, epigenetics.

 
Education: PhD and MS in Genetics & Molecular Biology, Federal University of Para, BrazilBS in Biomedicine, Federal University of Para, Brazil


Fun facts: In my free time, you may see me riding my bicycle or walking my cat on a leash.  





Faria Zafar, MA
Research Assistant II

Faria is a Research Assistant II that earned her Master in Molecular Biology from San Jose State University. She is currently working on generating induced pluripotent stem cells (iPSCs) from patient-specific fibroblasts.

Current Interests: Generation of dopaminergic neurons and oligodendrocytes to study disease mechanisms

Personal Research Goals: To develop more relevant and predictive drug screening and toxicology studies for clinical trail in Parkinson’s disease.

Education MA in Molecular Biology, San Jose State University,(EDG 2014)
  BS in Molecular & Cell Biology. University of California, Berkeley

Fun Facts: My passion is cooking and reading books.



Clinic Providers



Kristin Andruska, MD, PhD
Movement Disorders Specialist

Dr. Andruska is a board-certified neurologist who completed her Fellowship in Movement Disorders at Stanford University. She has expertise in the use of botulinum toxin and deep brain stimulation and is committed to the lifelong care of those with Parkinson’s disease and other movement disorders. She completed her Neurology Residency at Washington University in St. Louis, where she also served as the Chief Resident of Education. She was the recipient of the Irwin Levy Prize for Teaching and the Abdullah M. Nassief Award for Neurology.

She attended the University of Minnesota School of Medicine, graduating from its prestigious Medical Scientist Training Program with both an MD and PhD. Her research in neurobiology focused on disease models of spinocerebellar ataxia (SCA1) in the lab of Dr. Harry Orr, a world-renowned researcher credited with discovering the genetic abnormality causing the disease – a seminal discovery that has had wide-reaching impact in our understanding of neurodegenerative disorders. She received her undergraduate degree in Biology from the University of Texas at Austin.

Dr. Andruska also has significant research experience in Parkinson’s disease. While at Washington University, she focused on two important projects. First, analyzing where alpha-synuclein, the major constituent protein of Lewy Bodies, localizes in the brains of people with Parkinson’s. And second, using sophisticated genetic techniques and population analysis, identifying which genetic variants influence Parkinson’s risk, onset, and progression.





Anthony D Mosley, MD
Movement Disorder Specialist

Dr. Anthony D. Mosley is a board certified neurologist devoted to diagnosing and managing patients with Parkinson's disease and other movement disorders.  Dr. Mosley is a respected and exceptional physician focused on advancing our knowledge about movement disorders and improving the care of his patients. He brings a proven track record of patient focused medicine, and believes family and caretakers are an important partner in caring for individuals with Parkinson's disease. Dr. Mosley has expertise in the use of Botulinum toxin and Deep Brain Stimulation.

Prior to joining the Parkinson’s Institute and Clinical Center, Dr. Mosley was with NW Valley Neurology and Parkinson's Care Specialists in Glendale, AZ.  An experienced clinical researcher, he is a leader in the field of movement disorders.  Dr. Mosley is a published medical journal author, he co-wrote The Encyclopedia of Parkinson’s Disease and The A to Z of Parkinson’s Disease and he is an invited speaker at patient education and continuing medical educational events.

Dr. Mosley received his BS from the University of California in Berkeley, California; his MS from Stanford University in Stanford, California; and his MD from the University of California, San Francisco, California. Dr. Mosley completed his neurology residency at the University of California, Los Angeles School of Medicine, California.

If you would like to learn more about Dr. Mosley or schedule a future appointment with him, please contact Angie Valencia at (408) 542-5697.





Anthony Santiago, Dr.
Chief Medical Officer

Dr. Santiago most recently served as the Chief Medical Officer and a member of the Board of Directors, for Pathways Group, Inc., a professional consortium of clinicians, data scientists, educators, academic and industry translational researchers, professional athletes, and community leaders dedicated to improving the lives of people with neurodegenerative disorders. Dr. Santiago was responsible for the development, validation, and integration of medical content for its telehealth platform, designed to solve the challenges inherent to providing a virtual portal for sophisticated specialized patient care and clinical trial performance. He served as the liaison to academic, biomedical industry, healthcare systems, and commercial payers for strategic partnerships; led recruitment, supervision, and mentoring of medical directors; and provided oversight and coordination of multi-disciplinary, nationally-based operational teams responsible for telehealth platform development.

Prior to Pathways Group, Inc., Dr. Santiago was Associate Professor and Vice-Chair of the Department of Neurology at the University of Minnesota (UMN) School of Medicine, where he also served as the Chief of the Divisions of Movement Disorders and Ataxia; Director of the Neurology Residency Program; Director of the Movement Disorders / Neuromodulation Fellowship Program; and Core Administrative Director for the Udall Parkinson’s Disease Center of Excellence at the UMN – a National Institute of Health funded, highly-competitive, and prestigious initiative for which only eight institutes are designated in the US.

Prior to his arrival at the UMN, he was Associate Professor of Neurology and National Parkinson Foundation Center Director at the Muhammad Ali Parkinson Center of the Barrow Neurological Institute – a designated National Center of Excellence in care delivery, education, research, and patient outreach. He also served as the Director for Clinical and Translational Research in Neurodegenerative Disorders, and as the Director of the Movement Disorders/Neuromodulation Fellowship Program.

Dr. Santiago is an Alpha Omega Alpha graduate of the Albany Medical College in Albany, NY – one of the oldest and most prestigious private medical schools in the US – where he also completed his post‐graduate training in Neurology, a Fellowship in Movement Disorders/Neuromodulation, and was an Assistant Professor in the Neurology Department.

Dr. Santiago is a nationally-recognized expert in neurodegenerative disorders. He is a highly-active investigator for both industry-sponsored and publicly-funded research; author of numerous peer‐reviewed journal articles and book chapters; frequent lecturer for patient advocacy groups (the Davis Phinney Foundation, the Parkinson Foundation, the American Parkinson Disease Association, the Michael J Fox Foundation), industry partners in pharmacological and medical-device development, academic institutions and professional medical societies. He is a nationally‐awarded educator recognized for his outstanding didactic and clinical teaching; his trainees have gone on to the some of the most coveted fellowship and faculty positions in Neurology in the US. He is a consummate diagnostician and clinician, who emphasizes a holistic and humanistic approach to patient care, partnering with his patients and their families to create a relationship that is mutual and nurturing, but foremost, based upon accuracy and clarity as to the neurological condition to be addressed.

 





Barbara Luedtke, PT, MS, MPA
Director Ancillary Therapeutic Program

Barbara Luedtke joined the Parkinson’s Institute and Clinical Center as the new Director of Ancillary Therapeutic Program in October of 2015 and brings over 25 years of experience working with patients with neurological disorders including Parkinson’s disease. Ms. Luedtke’s care model aligns with the Institute--Parkinson’s is a lifelong disease process and requires the support of medical, research and rehabilitation services. At the Parkinson’s Institute and Clinical Center, a single location, comprehensive and evidence based services are provided to meet the needs of each patient. Ms.Luedtke has experienced the benefits of early intervention in Parkinson’s; the importance of patient understanding of the disease process, recognition of the benefits of exercise and how this gives a level of control to the patient to manage the disease and live a more normal lifestyle. Also, those with more progressive disease process therapy will improve their functional levels from the introduction or re-introduction of therapy programs such as LSVT BIG and other therapy treatment interventions.

For the last five years Barbara has been the Physical Therapy Manager at Laguna Honda Hospital and Rehabilitation Center (LHH) where she worked with patients with TBI, SCI, trauma, neurological disorders and psychological issues.  Ms. Luedtke was also the lead on the Falls Committee and operated the orthotics and prosthetics clinic.  Prior to LHH, Ms. Luedtke worked at Pathyways Home Health and Hospice where she instituted therapy programs in the home for multiple neurological and orthopedic diagnosis. Ms. Luedtke now has the opportunity to take her many years of experience and focus on one specialty area so that she may offer outstanding care for her patients and meet the therapy needs of her community.

Barbara received her Master of Science (MS), Physical Therapy degree from Barry University in Florida and her Master of Public Administration (MPA), concentration in Finance, from Norwich University in Vermont.  Barbara has worked in numerous settings across the country and in the UK, including hospitals, acute rehab, skilled nursing, out-patient and home health.  

If you would like to learn more about Barbara or schedule a future appointment with her please contact Angie Valencia at (408) 542-5697.



Clinical Research



Andres Alvarez-Pinzon, MD, PhD
Director, Clinical Research & Clinical Studies

Dr. Alvarez-Pinzon has devoted his career to developing and providing rigorous, comprehensive, and compassionate care to those with Neurological Disorders. Dr. Alvarez-Pinzon has diverse experience working in the clinical and Biotech research arena and has worked in Academic and global pharmaceutical firms in different roles. He contributed to the establishment and growth of the Neurosciences Clinical research Department for Miami Neurosciences Center at Larkin, South Miami, Fl. During this time, Dr. Alvarez-Pinzon served as a Clinical Research Fellow for Neuro-Oncology and Gamma Knife Radiosurgery Clinical studies for Larking Community Hospital and Cleveland Clinic Florida.

He joined the Parkinson's Institute and Clinical Center in 2017 after spending 3 years on the Faculty of the Department of Public Health and Health Sciences at South University. He spent a two-year working as a Lead for Neurosciences Clinical Research for the Movement Disorders Center, Memory Center and Comprehensive Stroke Center in Tenet Florida Region. While there, he contributed to many clinical studies for Alzheimer’s, Parkinson’s, and Vascular Neurology trials. He has provided consultation or authored publications for many neurological and neurosciences peer review journals, including the American Academy of Neurological Surgeons (AANS). He is a recipient of an American Academy of Neurological and Orthopedic Surgeons 2016 (AANOS) award. The President of Colombia recognized Dr. Alvarez-Pinzon in 2016 for his resolute efforts to provide the best quality of care for patients with neurological disorders and be an exemplary scientific and physician representing for Colombia worldwide.

Dr. Alvarez-Pinzon is a summa cum laude graduate of University El Bosque, Colombia, where he also obtained his MD and MS degrees. He completed his Internship and Medical visitor training program in Neurology at Universita Biomedico Di Roma, Rome, Italy and a PhD training program in Neurosciences/Neuroplasticity at the University of Salamanca, Spain. He accomplished a Clinical Research fellowship at Cleveland Clinic Florida and Neurological Surgery Research Fellowship at Miami Neurosciences Center. His passion for healthcare and life sciences innovation pushed him to pursue an Executive Master Program in Health Care Administration from Florida Atlantic University and an MSc in Biotechnology & Biotech Enterprise at Johns Hopkins University focusing on healthcare management and Translational Medicine.



Clinic Staff



Randy Hoffman
Speech Therapy

Randy A. Hoffman, MA, CCCSLP

Speech and Language Pathologist

 

Randy A· Hoffman is certified nationally by the American Speech and Hearing Association- and licensed in the state of California- as a speech 'and language pathologist.  She holds a master's'. degree- and a certificate of. clinical competence. Experience includes working in acute ·care at the Northwestern University Medical Centers and the University of Illinois Medical Center.  Ms. Hoffman has worked in sub-acute settings throughout the Bay Area while maintaining a private practice in Palo- Alto. She is certified to provide treatment for Parkinson's patients by using the Lee Silverman Voice Treatment Program.  She is a recipient of the American Speech Hearing Associations of the ACE awards.  She actively participates in continuing- education programs in the areas of dysphasia- and voice Appropriate loudness, pitch and quality can be achieved with the assistance of speech language services.

 

She conducts one-on-one evaluations, assessing individual treatment needs.  She then evaluates and treats speech, voice, and swallowing disorders.  Many voice problems improve dramatically with the help of a speech language pathologist.  She has as undergraduate degree in speech and hearing disorders from the University of Illinois and holds a Master Degree in Speech and Language Pathology from the University of Tennessee.  She has a special certification in Lee Silverman Voice Therapy (LSVT), which is the most effective treatment for those who have Parkinson's disease and is experiencing speech and swallowing difficulties.



Board of Directors



Thomas D. Follett
Chairman

Mr. Follett serves as chair of the board of directors.  He is a graduate from Norte Dame University (BSE), University of Michigan (MSE) and Xavier University (MBA).   He was an engineer with GE designing aircraft engines.  In 1975, he joined Arthur Andersen which evolved into Accenture.  Mr. Follett became a partner in Accenture in 1985 and specialized in manufacturing systems design and installation in high tech industry.  He retired in 2000 after 25 years with Accenture.  Mr. Follett’s other civic work includes serving on the That Man May See as Chair of the Clinic Committee and is a past president of the ALS Association Bay Area Chapter.





Carrolee Barlow, MD, PhD
Chief Executive Officer

Dr. Barlow received her MD from the University of Utah, did a residency in Internal Medicine at The New York Hospital, Cornell Medical Center and a PhD in molecular and developmental biology at the Karrolinska Medical Nobel Institute in Stockholm, Sweden.  She joined the National Institutes of Health and completed medical subspecialty training in the field of endocrinology and a postdoctoral fellowship in neurogenetics at the National Human Genome Research Institute.  She was a faculty member of the Salk Institute in  translational medicine and genetics.  She has been a pharmaceutical executive since 2002, serving as Chief Scientific Officer and Chief Medical Officer of BrainCells, Inc.  Prior to BrainCells, she served as the Director of Molecular Neuroscience and Therapeutic Area Head for Stroke and Neurodegeneration at Merck Research Laboratories.  Her work has been published in many research journals.  She became CEO of the Parkinson’s Institute in 2014.





Peter C. Nosler
Vice Chair

Mr. Nosler is known for his collaborative approach to business leadership.  He and two partners started DPR Construction in 1990 and quickly transformed it from one of the fastest growing private companies in the region to one frequently named among the Best Places to Work.  Today, DPR is one of Silicon Valley’s biggest contractors with a client list that includes AT&T, Apple Computer, and Charles Schwab & Co.  Based in Redwood City, DPR focuses on projects for the biotech, pharmaceutical, and semiconductor markets. The employee-owned company completes about 125 major projects per year.  Over the last ten years DPR has been ranked in the top 50 general contractors in the country, has surpassed the billion dollar mark in sales, and has more than 2000 employees nationwide.  Mr. Nosler leads the DPR Foundation and is an active volunteer with the Monterey Bay Aquarium. 





Susan J. Foster
Secretary

Ms. Foster is a graduate of University of Nebraska (BA) and San Jose State Univeristy (MA).  She is a former Registered Nurse (RN).  She is a Partner with Learning Designs, Inc.  She has served as a marketing director with Alza Pharmaceuticals.   Her civic engagement includes The Stem Cell Advisors, Child Development Inc. and St. Francis High School. 





Ari Chaney, MBA
Board Member

Mr. Chaney has an MBA from the University of Chicago with High Honors, and a BS in Electrical Engineering from Worcester Polytechnic Institute with High Distinction. Most recently, he was the co-founder and CFO of Cellular Research, a genomics company developing a disruptive platform for precision biology research that was acquired by Becton Dickinson in 2015. Prior to building Cellular Research, Mr. Chaney was the Executive Director for Technology Translation for the Biodesign Program at Stanford University. Mr. Chaney is also the President and Founder of Leveraged Restructuring, where he has held Chairman or CEO positions with a number of companies including: Neucel Specialty Cellulose, Monona Wire Corporation, Rapid Rack Industries and Bomar Industries. Earlier in his career he served as Vice President, Supply Chain for Florida Power & Light (FPL), President and CEO of Aladdin Industries and within General Electric, President & GM of Midwest Electric, Plant Manager of the Austintown Products Plant in GE Lighting, and Manager of Corporate Business Development in GE Corporate. He currently serves on the Boards of Stealth Biosciences, 13.8, and The Parkinson’s Institute.





Sheldon Englehorn
Board Member

Sheldon is an entrepreneur who co-founded a life sciences tool company (now part of Thermo Fisher Scientific). He has served as an Alumni  regent of the University of California, and a trustee of the UC San Diego Foundation. An avid surfer, Sheldon is active with the Director’s Cabinet at Scripps Institution of Oceanography and received the Chancellor’s Medal in 2011.  He also serves as a board member of Nature and Culture International - a conservation organization founded by fellow P.I. director, Ivan Gaylor.





Ivan Gayler
Board Observer

Mr. Gayler is a long time real estate developer and founder of Del Mar Partnership.  Mr. Gayler founded Nature and Culture International in 1997.  Nature and Culture International has helped conserve 8.7 million acres of threated habitats in South America.  His work has been recognized with the San Diego Zoo’s Conservation Medal, an honor shared with Jane Goodall and David Attenborough.  





Judith A. Hemberger, PhD, MBA
Board Member

Dr. Hemberger received her PhD in Pharmacology form the University of Missouri, MBA from Rockhurst College and BS from Mount St. Scholastica College. She is the President and CEO of Suvica, a start-up biotech company. She has been a venture partner with Normura Phase 4 Ventures, Interim CEO of Zosano Pharma and Co-Founder, Executive Vice-President and COO, of Pharmion Corporation which was acquired by Celgene in 2008 for $2.7 billon.





Vernon Norviel, J.D.
Board Member

Mr. Norviel is a partner at Wilson Sonsini Goodrich & Rosati, where he leads the patents and innovation counseling practice. Mr. Norviel has three decades of experience in formulating successful strategies for life science companies and the development of their IP programs. He represents a wide variety of companies, as well as venture capital firms, in areas such as therapeutics, diagnostics, nanotechnology, genomics, proteomics, and personalized medicine. In fact, Mr. Norviel's interest in the field of personalized medicine prompted him to become the first attorney to have had his or her entire genome sequenced and made available in a public database. Before joining the firm in 2003, Mr. Norviel was the general counsel and corporate secretary of Perlegen Sciences, Inc., a start-up biotechnology company that scans the entire human genome for important therapeutic and diagnostic products. Previously, as senior vice president and general counsel, he was an early employee of Affymetrix, the biotechnology company that pioneered and developed DNA chip technology. He also had been a partner at Townsend and Townsend and Crew in Palo Alto.Mr. Norviel currently serves as a member of Wilson Sonsini Goodrich & Rosati's Compensation Committee and on the board of the WSGR Foundation, and previously served as a member of the Policy Committee. In addition, he is a lecturer in biotechnology law at UC Berkeley School of Law.





Michael Saign
Board Member

Michael Saign is a Senior Managing Director in Newmark Cornish & Carey’s Silicon Valley office and has consistently been one of the top ranked advisors within the firm. Mr. Saign specializes in developing and implementing customized real estate strategies for a diverse group of clients ranging from high growth startup ventures to global Fortune 500 corporations. In 2015, he directly managed the successful completion of over 1,000,000 square feet of transactions and was ranked within the Top 5 of all Newmark Cornish & Carey agents. Since joining the firm, Mr. Saign has completed over 275 assignments advising technology, life science and professional service companies
Mr. Saign is a native of Silicon Valley and graduate of Boston College where he rowed on the crew team. He currently serves on the Parkinson’s Institute and Clinical Center’s board of directors.



Management Team



Carrolee Barlow, MD, PhD
Chief Executive Officer

Carrolee Barlow, MD, PhD—renowned expert in neuroscience and neurodegeneration—joined the Parkinson’s Institute and Clinical Center as Chief Executive Officer (CEO) in February 2014. Dr. Barlow is the second CEO in the Institute’s 25 year history. She takes the reins from Dr. J. William Langston, who founded the organization in 1988.

Dr. Barlow’s previous work has spanned clinical care, laboratory and clinical research, academia, and industry. She is the former Chief Scientific Officer and Chief Medical Officer of BrainCells, Inc. in San Diego, California, a biotechnology company focused on the discovery and development of small molecules that stimulate adult hippocampal neurogenesis for the treatment of neurological and psychiatric disease using human neural stem cell technology. Prior to BrainCells, she served as the Director of Molecular Neuroscience and Therapeutic Area Head for Stroke and Neurodegeneration at Merck Research Laboratories where she was responsible for neuroscience biology, global exploratory, licensing, and full-phase efforts. Dr. Barlow has held a faculty position in the Laboratory of Genetics at the Salk Institute for Biological Studies in La Jolla, California. She also serves as an advisory board member for several biotechnology companies and disease foundations advancing therapies for rare diseases and disorders of the central nervous system (CNS).

Dr. Barlow received her MD from the University of Utah, did her residency in Internal Medicine at The New York Hospital, Cornell Medical Center, and went on to obtain a PhD in molecular and developmental biology at the Karolinska Medical Nobel Institute in Stockholm, Sweden. Shortly thereafter, she joined the National Institutes of Health and completed medical sub-specialty training in the field of endocrinology and a postdoctoral fellowship in neurogenetics at the National Human Genome Research Institute.





Brian Coulter
Chief Operations Officer

Brian is a seasoned Chief Operating Officer with experience in the non-profit sector, for-profit sector, and Federal government. With a formal education in finance, real estate, and business law, as well as, a Masters in Public Administration from the University of Southern California, Los Angeles, he has both academic and practical real-world experience.  He has provided leadership to multiple non-profits as a member of the Board of Directors, often holding the Treasurer position.

With over twenty-one years of experience increasing productivity, efficiency, and accountability, Brian has lead organizations through strong and weak markets. Consistently employing an innovative, can-do management style utilizing financial analysis skills, organizational management, wisdom, and understanding. 

As a Distinguished Alumni of the Finance, Real Estate, and Business Law Department, for California State Polytechnic University, Pomona he has served as Adjunct Professor teaching Corporate Finance to undergraduate students.  Brian is responsible for Finance, Contracting and Government Grants, Facilities, Information Technology and Legal.





Anthony Santiago, MD
Chief Medical Officer

Dr. Santiago is a nationally-recognized expert in neurodegenerative disorders and investigator for both industry-sponsored and publicly-funded research; author of
numerous peer reviewed journal articles and book chapters; frequent lecturer for patient
advocacy groups, industry partners in pharmacological and medical-device development, academic institutions and professional medical societies.

He is a highly-regarded and award-winning educator, recognized for his outstanding didactic and clinical teaching; his trainees have gone on to the some of the most coveted Fellowship and Faculty positions in Neurology in the US. He is a consummate diagnostician and clinician who emphasizes a holistic and humanistic approach to patient care, partnering with his patients and their families to create a relationship that is mutual and nurturing, but also values clinical accuracy and scientific rigor.

Dr. Santiago most recently served as the Chief Medical Officer and member of the Board of Directors for Pathways Group, Inc., a professional consortium of clinicians, data scientists,
educators, academic and industry translational researchers, professional athletes and community leaders dedicated to improving the lives of people with neurodegenerative disorders. He was responsible for the development, validation and integration of medical content for its telehealth platform designed to solve the challenges inherent to providing a virtual portal for specialized patient care and clinical trial performance.

Prior to Pathways Group, Inc., Dr. Santiago was Vice-Chair of the Department of Neurology at the University of Minnesota (UMN) School of Medicine, where he also served as the Chief of the Divisions of Movement Disorders and Ataxia; Director of the Neurology Residency Program; Director of the Movement Disorders / Neuromodulation Fellowship Program; and Administrative Core Director for the Udall Parkinson’s Disease Center of Excellence.

Prior to his arrival at the UMN, he was Associate Professor of Neurology and National Parkinson Foundation Center Director at the Muhammad Ali Parkinson Center of Barrow Neurological Institute – a designated National Center of Excellence in care delivery, education, research and community outreach. He also served as the Director for Clinical and Translational Research in Neurodegenerative Disorders and Director of the Movement Disorders / Neuromodulation Fellowship Program.

 

Dr. Santiago is an Alpha Omega Alpha graduate of the Albany Medical College in Albany, NY – where he also completed his post-graduate training in Neurology, a Fellowship in Movement Disorders / Neuromodulation, and was an Assistant Professor in the Neurology Department. He is a Summa Cum Laude graduate of Le Moyne College, where he received his Bachelor of Science in Psychology and Chemistry.

 





Joy Chesbrough
Chief Development Officer

Joy joined the Parkinson’s Institute and Clinical Center in November of 2017. Her passion for philanthropy and nonprofit leadership is evident in the way she approaches fundraising and donor relationships.

Joy is a talented nonprofit leader and communicator who has been published in various magazines, including San Diego Magazine. She has been a panel speaker and presented on philanthropy and co-created corporate partnerships and shared value at Scripps 4th & 5th Annual Natural Supplement conference, Scripps Center for Integrative Medicine Health conference, The American Board of Integrative Holistic Medicine conference in San Diego and in 2012 at the Phoenix Business Journal’s 2012 Corporate Partnership Summit. 

Professionally, Joy has spent 20 years as an executive nonprofit leader managing nonprofit organizations and teams. Joy holds an M.A in Communication from Regent’s School of Cinematography and an M.A. in Nonprofit Leadership and Management from the University of San Diego’s, Caster School of Nonprofit Leadership. 

Prior to running her own consulting firm, Philanthrovation, Joy focused on digital communication, grant writing, nonprofit major gift fundraising and strategic planning. She served in a senior executive role for MAP International, voted as one of CNN and Forbes top charities, and as a Senior Director at World Vision where she was part of a national fundraising team that launched the For Every Child campaign that raised $500 million to reach 10 million children worldwide. Moreover, Joy was the executive development director that worked with Scripps Health Foundation to raise investments for a premier Integrative Medicine Clinic and Center in La Jolla, California. And, as Petsmart Charities National Director of Philanthropy, she managed a philanthropy department and was part of an executive team that launched Petsmart’s first national cause-marketing campaign called, People Saving Pets where she raised over $100 million in investments. Joy’s spent the last ten years as a member of the Association for Fundraising Professionals (AFP) where she served on the board for two years as their Chair of Corporate Partnerships.

Joy is a distinguished member of Worldwide Who’s Who International and was recently awarded, Professional of the Year by the agency in 2013. 



675 Almanor Avenue | Sunnyvale, CA 94085
408.734.2800 main | 408.734.8455 fax (Main) | 408.734.9208 fax (Clinic Secure)